Phospholipase C (PLC)ɛ Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line

BACKGROUND: Primary therapy for patients with advanced prostate cancer (PCa) consists of androgen deprivation therapy targeting the androgen receptor (AR) axis. However, most tumors progress to castration-resistant prostate cancer (CRPC) within 18–24 months. The purpose of the present study was to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Mengjuan, Gao, Yingying, Li, Luo, Sun, Wei, Cheng, Honglin, Li, Ting, Niu, Lingfang, Du, Zhongbo, Quan, Zhen, Luo, Chunli, Wu, Xiaohou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Lab/In Vitro Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590100/
https://www.ncbi.nlm.nih.gov/pubmed/31201297
http://dx.doi.org/10.12659/MSM.915828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590100/
https://www.ncbi.nlm.nih.gov/pubmed/31201297
http://dx.doi.org/10.12659/MSM.915828

Ejemplares similares